EA at LU5, LI4, SP6 and ST36 could decrease the score of neurological deficit, reduce the volume of cerebral infarction and improve the degree of nerve cell injury, and inhibit NLRP3, pro-caspase-1, cleaved-caspase-1 p20, pro-IL-1β, cleaved-IL-1β and GSDMD protein expression (Cai et al., 2022). The gene discussed is CASP1; the disease is cerebral infarction.